Handai Candesartan anti-atherogenesis Trial on diabetic patients with hypertension using CT examination

Handai Candesartan anti-atherogenesis Trial on diabetic patients with hypertension using CT examination - Handai Cadesartan Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001453

Enrollment

100

Registered

2010-04-01

Start date

2008-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetic patients with hypertension

Interventions

Each subject has already received orally Candesartan (4 mg or 8 mg once daily). Same dose of candesrtan will be administered for a year. Each subject has already received orally Candesartan (4 mg or

systolic &lt

130 mmHg, diastolic &lt

80 mmHg.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients who understand the study procedures using explanatory notes and have given written informed consent to participate in the study, and, 2) Diabetic patients with hypertension receiving orally Candesartan (4 mg or 8 mg once daily) who be examined for the enhanced CT examination.

Exclusion criteria

Exclusion criteria: 1)Contraindications of candesartan 2)Contraindications of contrast agent

Design outcomes

Primary

Measure	Time frame
Changes of metabolic parameters, oxidative stress markers, adipocytokines, visceral fat areas, quality and quantity of coronary plaque, and carotid intima-media complex thickness (IMT), at the completion of treatment form baseline	—

Countries

Japan

Contacts

Public ContactKen Kishida

Osaka University Metabolic medicine

kkishida@imed2.med.osaka-u.ac.jp06-6879-3732

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026